Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT02135159 (BIRTH) (Clinical Trial/ Ado-Trastuzumab Emtansine)

Study Title
Patients With Brain Metastases From HER2-positive Breast Cancer (BIRTH) (NCT02135159)

Trial Description
The purpose of this study is to determine the optimal sequences of combined ado-trastuzumab emtansine (T-DM1, Kadcyla®; Genentech, Inc.) and whole-brain radiotherapy in patients presenting brain metastases from HER2-positive breast cancer in terms of acute toxicities and blood/cerebrospinal fluid T-DM1 pharmacokinetics.

This trial is sponsored by Institut du Cancer de Montpellier – Val d’Aurelle. (Montpellier Institute for Cancer) [1]

Study Data

  • Condition: HER2-positive Breast Cancer
  • Interventions:
    • Drugs used in this trial
    • Radiation: Brain Sequential RT
  • Phase: I
  • Estimated Enrollment: 36
  • Start: February 2014
  • Estimated Completion: March 2017
  • Last verified: May 2014

Study Schematic

(Coming soon)

Click here to Return to Drug map


Last Editorial review: July 31, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar